

J.P. Morgan invites you to participate in a special conference call

## Opportunities to Partner in Global Health Product Development

With

**Dr. David Shoultz**

Deputy Director, Strategy Planning & Management Bill & Melinda Gates Foundation

Over the past decade, the Bill & Melinda Gates Foundation (the "Foundation") has invested over \$2.5 billion to research and develop new health technologies that target poverty-related diseases disproportionately affecting developing country populations. During this time period, foundation grantees have successfully developed 19 life-saving products. Currently, the Foundation's product pipeline includes approximately 100 active candidates spanning nearly 20 diseases. This portfolio of innovative new global health products has matured, and the Foundation now expects to be advancing multiple late-stage programs in the next several years. Although late-stage clinical trials in developing countries require significantly greater funding than early-stage work, projects at this stage have been substantially de-risked and are on the brink of being able to deliver important new drugs, vaccines, diagnostics and preventatives to vulnerable populations in disease-endemic regions.

The maturation of the Foundation's global health product portfolio presents resource challenges but also offers an opportunity to make a meaningful difference in the health of millions of people.

Please join us for a more detailed overview of the current global health landscape and a preview of a unique new impact investment product designed to provide the Foundation's partners with low-cost capital for product development.

Date: Friday, October 28th, 2011

Time: 11:00am ET

Call-in Numbers:

Within the U.S.: [REDACTED]

Outside the U.S.: [REDACTED]

Passcode: GLOBAL HEALTH

To view the slides associated with this presentation, copy and paste the following URL into your

[REDACTED]  
[REDACTED]

Event password: "globalhealth" (no spaces)

Please RSVP to your J.P.Morgan Representative by Wednesday, October 26, 2011 if you are able to participate.

This invitation is confidential and intended solely for the use of J.P. Morgan professionals and the clients/prospects to whom it has been delivered. It is not to be reproduced or distributed to any other person except to the client's professional advisors. Private investments are subject to special risks and individuals must meet specific suitability standards before investing. This information does not constitute an offer to sell or a solicitation of an offer to invest in the Global Health Financing Facility (the "Facility"). No offering of interests of the Facility may be made by any literature, advertising or document in whatever form other than the confidential private placement memorandum. As a reminder, hedge funds (or funds of hedge funds), private equity funds, real estate funds and the like: Often engage in leveraging and other speculative investment practices that may increase the risk of investment loss; Can be highly illiquid; Are not required to provide periodic pricing or valuation information to investors; May involve complex tax structures and delays in distributing important tax information; Are not subject to the same regulatory requirements as mutual funds; and often charge high fees. Further, any number of conflicts of interest may exist in the context of the management and/or operation of any such fund. For complete information, please refer to the applicable offering memorandum. Bank products and services are offered by JPMorgan Chase Bank, N.A. and its affiliates. Securities are offered by J.P. Morgan Securities LLC, member NYSE, FINRA and SIPC. "J.P. Morgan Private Bank" is the marketing name for the private banking business conducted by JPMorgan Chase & Co. and its subsidiaries worldwide. This document is not intended as an offer or solicitation for the purchase or sale of any financial instrument.

Investment products: Not FDIC insured • No bank guarantee • May lose value